Natera stock analysis
Natera (45E) Stock Price & Analysis
45E Stock Chart & Stats
- Day’s Range
- EUR 251.70 - EUR 264.00
- 52-Week Range
- EUR 158.00 - EUR 391.30
- Previous Close
- EUR 273.70
- Volume
- N/A
- Average Volume (3M)
- 91
- Market Cap
- EUR 38.31B
- Enterprise Value
- EUR 58.69B
- Total Cash (Recent Filing)
- EUR 1.10B
- Total Debt (Recent Filing)
- EUR 238.84M
- Price to Earnings (P/E)
- ―
- Beta
- 0.32
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.15
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Testing Growth
Rapid growth in both testing volume and revenue indicates broadening clinical adoption across Natera’s platforms. Higher utilization can strengthen laboratory leverage, deepen clinician relationships, and provide a durable foundation for continued expansion across women’s health, organ health, and oncology.
Improving Margins And Cash Generation
Gross-margin expansion alongside renewed cash generation suggests improving economics as testing scales, pricing improves, and laboratory capacity is used more efficiently. This strengthens internal funding for product development and commercialization while reducing reliance on external capital over the coming quarters.
Expanding Oncology And Reimbursement Reach
Accelerating MRD adoption and broader Medicare coverage expand the addressable reimbursed market for Natera’s recurring monitoring tests. More covered indications can support repeat utilization, improve revenue visibility, and reinforce Signatera’s role in longitudinal cancer and transplant care.
Bears Say
Profitability Remains Negative
Despite strong revenue growth and narrower losses, Natera has not yet converted scale into sustainable operating profitability. Continued negative operating earnings leave less cushion for execution setbacks and make the business dependent on maintaining growth, margin progress, and disciplined investment.
Elevated Investment And Cost Pressure
Higher spending on trials, commercial initiatives, pharma services, and early detection can delay operating leverage even as revenue expands. Added cost of goods from newer products further pressures near-term margins, requiring successful scaling and cost-reduction work over the next 18 to 24 months.
Reimbursement Execution Uncertainty
Future growth depends partly on reimbursement decisions that remain outside Natera’s direct control. Delays or unfavorable outcomes for MolDX submissions could slow adoption and collections, while unresolved Japan pricing and reimbursement postpone the expected benefit from international expansion.
45E FAQ
What was Natera’s price range in the past 12 months?
What is Natera’s market cap?
When is Natera’s upcoming earnings report date?
How were Natera’s earnings last quarter?
Is Natera overvalued?
Does Natera pay dividends?
What is Natera’s EPS estimate?
How many shares outstanding does Natera have?
What happened to Natera’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Natera?
What is the TipRanks Smart Score and how is it calculated?
Natera Stock Smart Score
Company Description
Natera
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Solomon Moshkevich
- Employees
- 6,138
- Website
- www.natera.com
- Address
- 13011 McCallen Pass Building A, Austin, TX, 78753, US
Natera (45E) Earnings & Revenues
45E Company Deck
45E Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Natera reported record testing volumes, more than 40% revenue growth excluding true-ups, accelerating MRD adoption, improving underlying gross margins, cash generation, narrowed losses, new Medicare coverage, progress toward a Japan launch, strong clinical evidence, and raised full-year guidance. The main challenges were higher planned operating expenses, near-term COGS pressure from newer products, uncertain timing for additional reimbursement decisions, and significant investment in early cancer detection before it generates revenue. These challenges were presented alongside substantial growth momentum and a long-term plan to reach $6 billion in revenue.
View all DE:45E earnings summaries45E Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 1 | 0 | 11 |













